为研制广谱性禽流感口服疫苗，将4种禽流感病毒特异的基质蛋白2胞外区(matrix protein 2 ectodomain，M2e)多肽与黏膜免疫佐剂CTA1-DD串联，原核表达并纯化CTA1DD-AVI4M2e融合蛋白。以200 μg融合蛋白CTA1DD-AVI4M2e口服免疫BALB/c小鼠，结果显示实验组肠液IgA抗体效价和血清IgG抗体效价比对照组显著升高，血清中特异性IgG抗体效价达约360倍。分割的3段肠样中：第1段浸出液IgA抗体效价约为360倍，第2段约为120倍，第3段约为 9 720 倍。结果表明，本研究制备的CTA1DD-AVI4M2e具有显著口服免疫效果，为后续研究提供了基础。

In order to develop a universal oral vaccine for bird flu, four avian influenza virus-specific matrix protein 2 ectodomain (M2e) polypeptides were serially ligated with the mucosal immune adjuvant CTA1-DD, expressed in prokaryotic cells and purified as CTA1DD-AVI4M2e fusion protein. The BALB/c mice were orally immunized with the fusion protein CTA1DD-AVI4M2e. The results showed that the intestinal fluid IgA antibody titer and serum IgG antibody titer in the experimental group were significantly higher than those in the control group. The specific IgG antibody titer in the serum was about 360 times；in the first, second, and third segmented intestinal fluid, the IgA antibody titers were about 360 times, 120 times and 9 720 times, respectively. The results demonstrate that CTA1DD-AVI4M2e has a significant oral immune effect, providing the basis for further studies.